ReviewMicroorganisms2023
The Gut-Wrenching Effects of Cryptosporidiosis and Giardiasis in Children.
Open access · goldAbstract readReview
In one paragraph
Review in Microorganisms, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- Prevalence and molecular characterisation ofInternational journal for parasitology. Parasites and wildlife · 2026Article
- From parasite-induced immune activation to neuroinflammation and behavioral dysfunction: convergent mechanisms across protozoa and helminths: a review.Journal of neuroinflammation · 2026Review
- The triple threat of Cryptosporidium, Giardia, and Entamoeba infections in Nigerian children.Scientific reports · 2026Article
- Infectious Diarrhea in Early Childhood across the Global South: Etiologic Diversity and Pathogenic Mechanisms.ACS infectious diseases · 2026Review
- Detection of Cryptosporidium and Giardia duodenalis in Reptiles in Thailand.Veterinary medicine and science · 2026Article
- Giardiasis in the Immunocompromised: A Case Series Highlighting Diagnostic Pitfalls and Treatment Challenges.Cureus · 2025Article
- Coprological and molecular prevalence of Cryptosporidium and Giardia in cattle and irrigation water from Beni-Suef Governorate, Egypt.Scientific reports · 2025Article
- The development and excretion of Toxoplasma gondii oocyst manipulate the gut microbiota in its definitive host.Parasites & vectors · 2025Article
- Review
- Prevalence and risk factors ofVeterinarni medicina · 2025Article
- Gut Barrier Dysfunction and Microbiota Variations in Cryptosporidiosis: A Comprehensive Review.Veterinary sciences · 2025Review
- Occurrence and Multi-Locus Genotyping ofAnimals : an open access journal from MDPI · 2025Article
- Liver parasites: A global endemic and journey from infestation to intervention.World journal of gastroenterology · 2025Article
- Cryptosporidiosis: A global threat to human and animal health.Open veterinary journal · 2025Review
- Leading Paediatric Infectious Diseases-Current Trends, Gaps, and Future Prospects in Oral Pharmacotherapeutic Interventions.Pharmaceutics · 2024Review
- Cryptosporidium parvum disrupts intestinal epithelial barrier in neonatal mice through downregulation of cell junction molecules.PLoS neglected tropical diseases · 2024Article
- Cryptosporidium spp. prevalence in the general population in Guinea: first large-scale screening study.Parasite (Paris, France) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Mayuri PrabakaranCenter for Emerging and Reemerging Infectious Diseases (CERID), Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA 98109, USA.
Lyssa J WeibleCenter for Emerging and Reemerging Infectious Diseases (CERID), Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA 98109, USA.
Joshua D ChamplainCenter for Emerging and Reemerging Infectious Diseases (CERID), Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA 98109, USA.
Ryan Ye JiangCenter for Emerging and Reemerging Infectious Diseases (CERID), Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA 98109, USA.
Katalina BiondiHuman Center for Artificial Intelligence, Department of Computer Science, University of Central Florida, Orlando, FL 32816, USA.
Ana A WeilCenter for Emerging and Reemerging Infectious Diseases (CERID), Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA 98109, USA.
Wesley C Van VoorhisCenter for Emerging and Reemerging Infectious Diseases (CERID), Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA 98109, USA.
Kayode K OjoCenter for Emerging and Reemerging Infectious Diseases (CERID), Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA 98109, USA.ORCID 0000-0002-2007-2170
University of Washington · USUniversity of Central Florida · US
Funding
Bumped Kinase Inhibitors: Novel Therapeutics for Cryptosporidiosis&ToxoplasmosisR01AI111341 · NIAID · UNIVERSITY OF WASHINGTON · PI VAN VOORHIS, WESLEY C · 2014 to 2018
$6.4MCalcium Dependent Protein Kinase 1 as a drug target for T. gondii and C. parvumR01AI089441 · NIAID · UNIVERSITY OF WASHINGTON · PI MERRITT, ETHAN A, PARSONS, MARILYN · 2010 to 2014
$5.0MBumped-Kinase Inhibitor Drug Development for ToxoplasmosisR01HD102487 · NICHD · UNIVERSITY OF WASHINGTON · PI VAN VOORHIS, WESLEY C · 2021 to 2025
$3.3MMethionyl-tRNA Synthetase inhibitors can be developed as novel Giardiasis therapeuticsR01AI158524 · NIAID · UNIVERSITY OF WASHINGTON · PI OJO, KAYODE K · 2021 to 2024
$2.8MDual Use Therapeutics for Cryptosporidiosis, Toxoplasmosis, and NeosporosisR01HD080670 · NICHD · UNIVERSITY OF WASHINGTON · PI VAN VOORHIS, WESLEY C · 2014 to 2018
$1.9MDevelopment of Cell-active Giardia lamblia Methionyl-tRNA Synthetase Inhibitors as a New Therapeutic for GiardiasisR56AI146067 · NIAID · UNIVERSITY OF WASHINGTON · PI OJO, KAYODE K · 2020 to 2020
$766kDevelopment of Dual Efficacy Therapeutic Against Cryptosporidiosis and GiardiasisR21AI140881 · NIAID · UNIVERSITY OF WASHINGTON · PI OJO, KAYODE K · 2019 to 2020
$477kNIAID NIH HHS R01 AI089441NIAID NIH HHS R01 AI111341NIAID NIH HHS R01 AI158524NIAID NIH HHS R21 AI140881NIAID NIH HHS R56 AI146067NICHD NIH HHS R01 HD080670NICHD NIH HHS R01 HD102487NIH HHS R01AI089441NIH HHS R01AI111341NIH HHS R01AI158524NIH HHS R01HD080670NIH HHS R01 HD102487NIH HHS R21AI140881NIH HHS R56AI146067
Abstract
PubMed holds no abstract for this paper.
Indexed as
children’s gut healthcryptosporidiosis and giardiasisgut microbiotaimmunocompromisedundernutrition
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.